$Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma$

Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2024-07, Vol.205 (1), p.368-372
Hauptverfasser:	Othman, Tamer, Baird, John H., Pak, Stacy, Mei, Matthew, Herrera, Alex F., Mansour, Joshua, Shouse, Geoffrey, Sahebi, Firoozeh, Spielberger, Ricardo, Cai, Ji‐Lian, Farol, Leonardo, Godfrey, James, Kallam, Avyakta, Phillips, Tycel, Popplewell, Leslie, Siddiqi, Tanya, Forman, Stephen, Budde, Lihua E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antigens, CD19 - immunology Biological Products - therapeutic use CD19 antigen Cell therapy Female Humans Immunotherapy, Adoptive - methods Lymphoma Lymphoma, Large B-Cell, Diffuse - immunology Lymphoma, Large B-Cell, Diffuse - therapy Male Middle Aged Receptors, Chimeric Antigen - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	0007-1048 1365-2141 1365-2141
DOI:	10.1111/bjh.19521